Evidence map›Paper›PMID 30993405›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2019

Two data pre-processing workflows to facilitate the discovery of biomarkers by 2D NMR metabolomics.

Baptiste Féraud, Justine Leenders, Estelle Martineau, Patrick Giraudeau, Bernadette Govaerts, Pascal de Tullio

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Baptiste FéraudInstitute of Statistics, Biostatistics and Actuarial Sciences (ISBA), Université Catholique de Louvain (UCL), Voie du Roman Pays 20, bte L1.04.01, 1348, Louvain-la-Neuve, Belgium. baptiste.feraud@uclouvain.be.ORCID 0000-0002-9012-2313
Justine LeendersCenter for Interdisciplinary Research on Medicines (CIRM), Metabolomics group, Université de Liège (ULg), Liege, Belgium.
Estelle MartineauEBSI Team, Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation (CEISAM), CNRS, UMR 6230, Université de Nantes, Nantes, France.
Patrick GiraudeauEBSI Team, Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation (CEISAM), CNRS, UMR 6230, Université de Nantes, Nantes, France.
Bernadette GovaertsInstitute of Statistics, Biostatistics and Actuarial Sciences (ISBA), Université Catholique de Louvain (UCL), Voie du Roman Pays 20, bte L1.04.01, 1348, Louvain-la-Neuve, Belgium.
Pascal de TullioCenter for Interdisciplinary Research on Medicines (CIRM), Metabolomics group, Université de Liège (ULg), Liege, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe pre-processing of analytical data in metabolomics must be considered as a whole to allow the construction of a global and unique object for any further simultaneous data analysis or multivariate statistical modelling. For 1D

objectiveBy considering the added value of a second dimension, the objective is to propose two workflows dedicated to 2D NMR data handling and preparation (the Global Peak List and Vectorization approaches) and to compare them (with respect to each other and with 1D standards). This will allow to detect which methodology is the best in terms of amount of metabolomic content and to explore the advantages of the selected workflow in distinguishing among treatment groups and identifying relevant biomarkers. Therefore, this paper explores both the necessity of novel 2D pre-processing workflows, the evaluation of their quality and the evaluation of their performance in the subsequent determination of accurate (2D) biomarkers.

methodsTo select the more informative data source, MIC (Metabolomic Informative Content) indexes are used, based on clustering and inertia measures of quality. Then, to highlight biomarkers or critical spectral zones, the PLS-DA model is used, along with more advanced sparse algorithms (sPLS and L-sOPLS).

resultsResults are discussed according to two different experimental designs (one which is unsupervised and based on human urine samples, and the other which is controlled and based on spiked serum media). MIC indexes are shown, leading to the choice of the more relevant workflow to use thereafter. Finally, biomarkers are provided for each case and the predictive power of each candidate model is assessed with cross-validated measures of RMSEP.

conclusionIn conclusion, it is shown that no solution can be universally the best in every case, but that 2D experiments allow to clearly find relevant cross peak biomarkers even with a poor initial separability between groups. The MIC measures linked with the candidate workflows (2D GPL, 2D vectorization, 1D, and with specific parameters) lead to visualize which data set must be used as a priority to more easily find biomarkers. The diversity of data sources, mainly 1D versus 2D, may often lead to complementary or confirmatory results.

Indexed as

AlgorithmsBiomarkersComputational BiologyData AnalysisMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMetabolomicsSoftwareWorkflowBiomarkers1H-NMR2D NMRBiomarker discoveryCOSY spectraL-sOPLSMetabolomic informative content (MIC)PLSPre-prossessing workflowssPLS

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.